Barclays reaffirms its 'overweight' recommendation and raises its target price for Sanofi from €95 to €105, as 'figures have already been reset, on the strength of a solid R&D day' and what it sees as 'continued positive momentum for Dupixent'.

For the quarter, the broker said he was 2% below consensus on sales, and in line with consensus on business EPS, and for 2024, he said he was 'in line on both indicators (but above on the products that matter)'.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.